Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons

This study has been completed.
Glaxo Wellcome
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: November 2, 1999
Last updated: April 27, 2012
Last verified: April 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 1995
  Estimated Primary Completion Date: No date given